Edition:
United States

Valeant Pharmaceuticals International Inc (VRX.TO)

VRX.TO on Toronto Stock Exchange

22.55CAD
23 Apr 2018
Change (% chg)

$0.61 (+2.78%)
Prev Close
$21.94
Open
$22.08
Day's High
$22.85
Day's Low
$21.98
Volume
983,322
Avg. Vol
1,822,228
52-wk High
$30.56
52-wk Low
$11.20

Chart for

About

Valeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment,... (more)

Overall

Beta: -0.34
Market Cap(Mil.): $5,997.23
Shares Outstanding(Mil.): 348.71
Dividend: --
Yield (%): --

Financials

  VRX.TO Industry Sector
P/E (TTM): 4.31 30.21 32.78
EPS (TTM): 4.07 -- --
ROI: 3.92 13.61 13.21
ROE: 31.75 15.28 15.01

BRIEF-U.S. International Trade Commission Says Will Probe Certain Clidinium Bromide-Containing Products After Valeant Pharmaceuticals Filed Complaint -Statement

* U.S. INTERNATIONAL TRADE COMMISSION SAYS WILL PROBE CERTAIN CLIDINIUM BROMIDE-CONTAINING PRODUCTS AFTER VALEANT PHARMACEUTICALS FILED COMPLAINT -STATEMENT Source text for Eikon: Further company coverage:

Apr 18 2018

Canada seeks U.S. help to solve EpiPen shortage

TORONTO Canada said on Tuesday it is working with the U.S. Food and Drug Administration to access supplies of Mylan N.V.'s EpiPen emergency allergy antidote amid a growing shortage that has spared the United States.

Apr 17 2018

UPDATE 3-Canada seeks U.S. help to solve EpiPen shortage

TORONTO, April 17 Canada said on Tuesday it is working with the U.S. Food and Drug Administration to access supplies of Mylan N.V.'s EpiPen emergency allergy antidote amid a growing shortage that has spared the United States.

Apr 17 2018

BRIEF-Valeant To Purchase Up To $1.5 Bln Aggregate Principal Of Outstanding Notes​

March 26 Valeant Pharmaceuticals International Inc:

Mar 26 2018

BRIEF-Valeant Says Joseph Papa's 2017 Total Compensation $4.9 Mln

March 21 Valeant Pharmaceuticals International Inc:

Mar 21 2018

BRIEF-Valeant Announces Launch Of Private Offering Of Senior Notes

March 12 Valeant Pharmaceuticals International Inc:

Mar 12 2018

BRIEF-Valeant Files For Potential Mixed Shelf Offering Size Not Disclosed - SEC Filing

March 2 Valeant Pharmaceuticals International Inc:

Mar 02 2018

Competitors

Earnings vs. Estimates